apceth Extends Top Management

Ralf Huss will focus on the pre-clinical and early development of cell-based therapeutics and external innovation in the company that is specialized on the translational development and manufacturing of innovative cell therapy products. CEO Dr Christine Günther warmly welcomes the strengthening of the apceth management team. Majority shareholder Dr Thomas Strüngmann comments: “Ralf Huss has been a founding member of apceth. We are delighted that he has now decided to join the operational team in apceth”.

Expertise in the development of cell therapy products
Prof. Ralf Huss has many years of experience in academic research and in the international pharmaceutical industry. After studying medicine and spending time in research in Switzerland and the USA, where he focused on immunology and stem cell research, he became a consultant and Professor of Pathology at the Ludwig Maximilian University in Munich. In addition to other positions, Ralf Huss is still Adjunct Professor for Regenerative Medicine at Wake Forest Institute for Regenerative Medicine in Winston-Salem (USA). Since 2005, he has worked at Roche Diagnostics GmbH in Pharmaceutical Research & Early Development (pRED) in Penzberg, Germany.

Dr Christine Günther is an expert in the areas of clinical stem cell transplantation, transplantation immunology and cell therapy. As a haematologist/oncologist, Dr Günther has held various positions at the University Hospital and the Schwabing City Hospital in Munich and, prior to joining apceth in 2008, she worked for several years as Qualified Person and Medical Director in a public stem cell and cord blood bank. In addition, she focused on the development and licensing of an umbilical cord blood product for use in the treatment of malignant diseases.